Rishi Gupta - 03 Jun 2024 Form 4 Insider Report for Turnstone Biologics Corp. (TSBX)

Role: Director, 10%+ Owner
Signature: /s/ Venkat Ramanan, Attorney-in-Fact
Issuer symbol: TSBX
Transactions as of: 03 Jun 2024
Net transactions value: $0
Form type: 4
Filing time: 02 Jul 2024, 16:45:12 UTC
Previous filing: 20 May 2024
Next filing: 10 Feb 2025
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TSBX	Stock Option (Right to Buy)	Award	$0	+12,770		$0.000000	12,770	03 Jun 2024	Common Stock	12,770	$2.69	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares subject to the option will vest on the earlier of June 3, 2025 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date.
F2	Pursuant to an agreement between OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefits thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VI, LP.

Content

The shares subject to the option will vest on the earlier of June 3, 2025 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date.

Pursuant to an agreement between OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefits thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VI, LP.